Denali Therapeutics (DNLI) Return on Equity (2018 - 2024)
Historic Return on Equity for Denali Therapeutics (DNLI) over the last 8 years, with Q3 2025 value amounting to 0.12%.
- Denali Therapeutics' Return on Equity rose 2000.0% to 0.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.12%, marking a year-over-year increase of 2000.0%. This contributed to the annual value of 0.37% for FY2024, which is 2300.0% down from last year.
- Per Denali Therapeutics' latest filing, its Return on Equity stood at 0.12% for Q3 2025, which was up 2000.0% from 0.21% recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Return on Equity ranged from a high of 0.05% in Q2 2021 and a low of 0.37% during Q1 2023
- Over the past 5 years, Denali Therapeutics' median Return on Equity value was 0.27% (recorded in 2025), while the average stood at 0.2%.
- As far as peak fluctuations go, Denali Therapeutics' Return on Equity soared by 5100bps in 2021, and later tumbled by -3900bps in 2022.
- Over the past 5 years, Denali Therapeutics' Return on Equity (Quarter) stood at 0.29% in 2021, then decreased by -20bps to 0.35% in 2022, then skyrocketed by 62bps to 0.14% in 2023, then plummeted by -146bps to 0.33% in 2024, then surged by 65bps to 0.12% in 2025.
- Its last three reported values are 0.12% in Q3 2025, 0.21% for Q2 2025, and 0.27% during Q1 2025.